August 9, 2022 Dataset Open Access

Moldovan, Rares-Petru; Gündel, Daniel; Deuther-Conrad, Winnie; Ueberham, Lea; Kaur, Sarandeep; Otikova, Elina; Teodoro, Rodrigo; Lai, Thu Hang; Clauß, Oliver; Scheunemann, Matthias; Bormans, Guy; Kopka, Klaus; Bachmann, Michael; Brust, Peter

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Moldovan, Rares-Petru</dc:creator>
  <dc:creator>Gündel, Daniel</dc:creator>
  <dc:creator>Deuther-Conrad, Winnie</dc:creator>
  <dc:creator>Ueberham, Lea</dc:creator>
  <dc:creator>Kaur, Sarandeep</dc:creator>
  <dc:creator>Otikova, Elina</dc:creator>
  <dc:creator>Teodoro, Rodrigo</dc:creator>
  <dc:creator>Lai, Thu Hang</dc:creator>
  <dc:creator>Clauß, Oliver</dc:creator>
  <dc:creator>Scheunemann, Matthias</dc:creator>
  <dc:creator>Bormans, Guy</dc:creator>
  <dc:creator>Kopka, Klaus</dc:creator>
  <dc:creator>Bachmann, Michael</dc:creator>
  <dc:creator>Brust, Peter</dc:creator>
  <dc:date>2022-08-09</dc:date>
  <dc:description>The cannabinoid receptor type 2 (CB2R) is an attractive target for diagnosis and therapy of neurodegenerative diseases and cancer. Recently, we reported a novel naphthyrid-2-one based positron-emission tomography (PET) radioligand for imaging of the CB2R in the brain ([18F]5). In this study we aimed at the development of a novel 18F-labeled CB2R radioligand with improved binding properties and metabolic stability. Starting from the structure of 5, we developed a novel series of fluorinated derivatives by modifying the substituents at the naphthyrid-2-one subunit. Compound 28 (LU13) was identified with the highest binding affinity and selectivity versus CB1R (CB2RKi = 0.6 nM; CB1RKi/CB2RKi &gt; 1000) and was selected for radiolabeling with 18F and biological characterization. The radiofluorination was performed starting from the corresponding bromo-precursor (31) bearing a fully deuterated N-alkyl chain to protect against defluorination. The in vitro evaluation of [18F]LU13 proved the high binding affinity of the radioligand towards rat (rCB2RKD = 0.2 nM) and human (hCB2RKD = 1.1 nM) CB2R. Metabolism studies in mice revealed a metabolic stability at 30 min p.i. with fractions of parent compound of &gt;80% in the brain and 90% in the spleen with only trace of defluorination products detected in plasma. PET imaging in a rat model of vector-based/related overexpression in the striatum revealed a high signal to background ratio, demonstrating the ability of [18F]LU13 to reach and selectively label the hCB2R in the brain. Thus, [18F]LU13 is a novel and highly promising PET radioligand for the imaging of up regulated CB2R expression under pathological conditions in the brain.</dc:description>
  <dc:identifier>https://rodare.hzdr.de/record/1381</dc:identifier>
  <dc:identifier>10.14278/rodare.1381</dc:identifier>
  <dc:identifier>oai:rodare.hzdr.de:1381</dc:identifier>
  <dc:relation>url:https://www.hzdr.de/publications/Publ-34030</dc:relation>
  <dc:relation>url:https://www.hzdr.de/publications/Publ-33987</dc:relation>
  <dc:relation>doi:10.14278/rodare.1380</dc:relation>
  <dc:relation>url:https://rodare.hzdr.de/communities/health</dc:relation>
  <dc:relation>url:https://rodare.hzdr.de/communities/rodare</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by/4.0/legalcode</dc:rights>
  <dc:subject>cannabinoid receptor type 2</dc:subject>
  <dc:subject>naphthyrid-2-one</dc:subject>
  <dc:subject>binding affinity</dc:subject>
  <dc:title>Data Publication: Structure-Based Design, Optimization and Development of [18F]LU13, a novel radioligand for CB2R Imaging in the Brain with PET</dc:title>
  <dc:type>info:eu-repo/semantics/other</dc:type>
  <dc:type>dataset</dc:type>
</oai_dc:dc>